~~<i id='293D12C904'><strike id='293D12C904'><tt id='293D12C904'><pre id='293D12C904'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：comprehensive 2025-10-06 08:28:24 Page View：2495

AP/Richard Drew

Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development.

The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry.

Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What is the Turing Test that determines if computers can think?
Next article： Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

comprehensive

Apple is now the first public company to be valued at $3 trillion

6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

What is the Turing Test that determines if computers can think?

3:26AlanTuring(1912-1954),computerscientistandcryptologistinstrumentalinbreakingGermany's'enigma'mac

New air purifier tech could be key to improving indoor air quality

AdobeUntiltheearly20thcentury,Americaregularlyexperiencedbrutallydestructiveurbanfires.Conflagration

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul